Biotech deal-making grows in importance as Big Pharma restructures...
"The bottom line on deals is likely to keep the business development teams busy in 2012. Big Pharma still needs new technology and new products, and they're still often not very good at growing them without a lot of help. For biotechs with smart science and an inside track on a novel therapy, there are buyers willing to come to the table. They'll be back at the bargaining next year as well."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)